KainosMed and BidTech Collaborate on Atopy Treatment Research... "Global Exclusive Rights Possible"

[Asia Economy Reporter Hyunseok Yoo] Kainosmed announced on the 9th that it has signed a joint research agreement with Vidtech aimed at identifying a candidate for an atopic dermatitis treatment. Through this agreement, Kainosmed has obtained an option to acquire exclusive rights for the global commercialization of the atopic dermatitis treatment candidate substance initially developed by Vidtech.

Under this joint research agreement, Kainosmed plans to evaluate the drug commercialization potential through pharmacological, pharmacokinetic tests, and preliminary toxicity tests of the preclinical candidate substance, while Vidtech will be responsible for synthesizing and providing the preclinical candidate substance, confirming the molecular biological mechanism of action (MOA), and target validation. After approximately one year of joint research, if the technology transfer contract is finalized, Kainosmed will take charge of preclinical and clinical development and carry out commercialization development.

According to initial research results conducted by Vidtech and Professor Bonggeon Joo’s team at Sogang University, Vidtech’s drugs demonstrated positive therapeutic potential in animal models by suppressing cytokine secretion related to atopy and suggesting possible clinical efficacy. It is expected to meet the medical needs for atopic dermatitis treatments that reduce the side effects of commonly used corticosteroids while maintaining efficacy.

A Kainosmed official stated, "As demand for highly effective and safe atopic dermatitis treatments grows, Kainosmed will confirm the potential of the drug to enter the atopic dermatitis treatment market with significant unmet needs through joint research with Vidtech." He added, "It is especially meaningful that Kainosmed has obtained exclusive rights not only for some regions such as Asia but for the global market."